Drug intelligence / Profile preview

monosialotetrahexosylganglioside + paclitaxel

Development stage: Preclinical
Lead developer: Fidia Farmaceutici
Modality: Small Molecules
Administration: Intravenous

Overview

Monosialotetrahexosylganglioside (GM1) + paclitaxel is a combination therapy being investigated for the prevention or treatment of chemotherapy-induced peripheral neuropathy (CIPN). GM1 is a neuroprotective glycosphingolipid that repairs nerves and has antioxidant properties, while paclitaxel is a chemotherapeutic agent commonly used in breast cancer treatment that is known to cause peripheral neurotoxicity. The combination is being studied to determine if GM1 can reduce or prevent the neuropathy caused by paclitaxel treatment.

Targets

TUBB (Tubulin (alpha and beta subunits))GEM (Neuronal plasma membrane ganglioside-rich microdomain)

Beyond the preview

Go deeper on monosialotetrahexosylganglioside + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on monosialotetrahexosylganglioside + paclitaxel.

Explore the full profile